In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.04% change from the preceding trading day.

Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 ...

Additionally, HIMS has minimal debt levels, with a debt-to-equity ratio below 1%, and holds $300 million in cash, representing a 42% cash-to-assets ratio. These figures underscore HIMS' financial ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

While the Toronto Blue Jays are off today, they were staring down the barrel of a roster decision on Friday when Nathan Lukes ...

Citi analyst Daniel Grosslight maintained a Hold rating on Cardinal Health (CAH – Research Report) today and set a price target of $140.00. The ...

In a report released today, Daniel Grosslight from Citi maintained a Buy rating on McKesson (MCK – Research Report), with a price target of ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...